Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Breast Tumor - a Pilot Study View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2010-2014

ABSTRACT

A number of prognostic and/or predictive genomic signatures for breast cancer have been developed by Genome Institute of Singapore (GIS). In the past 1 year, GIS has developed protocols and methods to conduct expression assays from formalin-fixed, paraffin-embedded (FFPE) tumor specimens. A study on 800 tumor samples is planned to analyze these gene signatures and compare them with conventional clinical prognosticators and predictors. As the investigators plan to use archival tumor samples that dates back to the 1990s, the aim of this pilot study is to first analyze 10 anonymized samples to determine the feasibility of running these assays on old archival blocks. The information generated will help us determine whether very old samples (diagnosed before 2000) may be selected for the actual study. Detailed Description Up to 10 archival breast tumor blocks will be obtained from the Department of Pathology, NUH - half of these blocks will be from patients who were diagnosed before year 2000, and the other half of the blocks will be from patients diagnosed between year 2000-2005 (control specimens). Basic tumor and patient information will be collected without patient identifiers - grade, stage, ER/PR/HER2 status, treatment received, outcome data. 8-10 ten-micron sections will be cut from each tumor block. RNA will be extracted from the tumor sections using the Roche High Pure FFPE RNA Micro Kit. RNA will be profiled using the Illumina Veracode assay and the Affymetrix Quantigene assay. RNA extraction and gene expression profiling will be performed by collabroators at the Genome Institute of Singapore. More... »

URL

https://clinicaltrials.gov/show/NCT01247467

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "A number of prognostic and/or predictive genomic signatures for breast cancer have been developed by Genome Institute of Singapore (GIS). In the past 1 year, GIS has developed protocols and methods to conduct expression assays from formalin-fixed, paraffin-embedded (FFPE) tumor specimens. A study on 800 tumor samples is planned to analyze these gene signatures and compare them with conventional clinical prognosticators and predictors. As the investigators plan to use archival tumor samples that dates back to the 1990s, the aim of this pilot study is to first analyze 10 anonymized samples to determine the feasibility of running these assays on old archival blocks. The information generated will help us determine whether very old samples (diagnosed before 2000) may be selected for the actual study.\n\nDetailed Description\nUp to 10 archival breast tumor blocks will be obtained from the Department of Pathology, NUH - half of these blocks will be from patients who were diagnosed before year 2000, and the other half of the blocks will be from patients diagnosed between year 2000-2005 (control specimens). Basic tumor and patient information will be collected without patient identifiers - grade, stage, ER/PR/HER2 status, treatment received, outcome data. 8-10 ten-micron sections will be cut from each tumor block. RNA will be extracted from the tumor sections using the Roche High Pure FFPE RNA Micro Kit. RNA will be profiled using the Illumina Veracode assay and the Affymetrix Quantigene assay. RNA extraction and gene expression profiling will be performed by collabroators at the Genome Institute of Singapore.", 
    "endDate": "2014-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01247467", 
    "keywords": [
      "genomic signature", 
      "paraffin", 
      "Pilot Project", 
      "Breast Neoplasm", 
      "Institute", 
      "developed protocol", 
      "method", 
      "expression assay", 
      "FFPE", 
      "tumor specimen", 
      "tumor sample", 
      "gene signature", 
      "prognosticator", 
      "predictor", 
      "date", 
      "sample", 
      "feasibility", 
      "assay", 
      "old sample", 
      "breast", 
      "Department of Pathology", 
      "half", 
      "patient", 
      "control specimen", 
      "basic", 
      "patient information", 
      "patient identifier", 
      "grade", 
      "stage", 
      "status", 
      "outcome data", 
      "section", 
      "Neoplasm", 
      "RNA", 
      "tumor section", 
      "Roche", 
      "micro", 
      "Illumina", 
      "Affymetrix", 
      "RNA extraction", 
      "gene expression profiling"
    ], 
    "name": "Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Breast Tumor - a Pilot Study", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01247467"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00009.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.412106.0", 
        "type": "Organization"
      }
    ], 
    "startDate": "2010-08-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s10549-010-0788-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027199206", 
          "https://doi.org/10.1007/s10549-010-0788-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-010-0788-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027199206", 
          "https://doi.org/10.1007/s10549-010-0788-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq230", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042683953"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01247467"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01247467'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01247467'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01247467'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01247467'


 

This table displays all metadata directly associated to this object as RDF triples.

67 TRIPLES      16 PREDICATES      58 URIs      50 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01247467 schema:about anzsrc-for:3142
2 schema:description A number of prognostic and/or predictive genomic signatures for breast cancer have been developed by Genome Institute of Singapore (GIS). In the past 1 year, GIS has developed protocols and methods to conduct expression assays from formalin-fixed, paraffin-embedded (FFPE) tumor specimens. A study on 800 tumor samples is planned to analyze these gene signatures and compare them with conventional clinical prognosticators and predictors. As the investigators plan to use archival tumor samples that dates back to the 1990s, the aim of this pilot study is to first analyze 10 anonymized samples to determine the feasibility of running these assays on old archival blocks. The information generated will help us determine whether very old samples (diagnosed before 2000) may be selected for the actual study. Detailed Description Up to 10 archival breast tumor blocks will be obtained from the Department of Pathology, NUH - half of these blocks will be from patients who were diagnosed before year 2000, and the other half of the blocks will be from patients diagnosed between year 2000-2005 (control specimens). Basic tumor and patient information will be collected without patient identifiers - grade, stage, ER/PR/HER2 status, treatment received, outcome data. 8-10 ten-micron sections will be cut from each tumor block. RNA will be extracted from the tumor sections using the Roche High Pure FFPE RNA Micro Kit. RNA will be profiled using the Illumina Veracode assay and the Affymetrix Quantigene assay. RNA extraction and gene expression profiling will be performed by collabroators at the Genome Institute of Singapore.
3 schema:endDate 2014-12-01T00:00:00Z
4 schema:keywords Affymetrix
5 Breast Neoplasm
6 Department of Pathology
7 FFPE
8 Illumina
9 Institute
10 Neoplasm
11 Pilot Project
12 RNA
13 RNA extraction
14 Roche
15 assay
16 basic
17 breast
18 control specimen
19 date
20 developed protocol
21 expression assay
22 feasibility
23 gene expression profiling
24 gene signature
25 genomic signature
26 grade
27 half
28 method
29 micro
30 old sample
31 outcome data
32 paraffin
33 patient
34 patient identifier
35 patient information
36 predictor
37 prognosticator
38 sample
39 section
40 stage
41 status
42 tumor sample
43 tumor section
44 tumor specimen
45 schema:name Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Breast Tumor - a Pilot Study
46 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01247467
47 schema:sdDatePublished 2019-03-07T15:23
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher N49dc95bb0e7742b0a652d889d082e9d5
50 schema:sponsor https://www.grid.ac/institutes/grid.412106.0
51 schema:startDate 2010-08-01T00:00:00Z
52 schema:subjectOf sg:pub.10.1007/s10549-010-0788-0
53 https://doi.org/10.1093/annonc/mdq230
54 schema:url https://clinicaltrials.gov/show/NCT01247467
55 sgo:license sg:explorer/license/
56 sgo:sdDataset clinical_trials
57 rdf:type schema:MedicalStudy
58 N49dc95bb0e7742b0a652d889d082e9d5 schema:name Springer Nature - SN SciGraph project
59 rdf:type schema:Organization
60 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
61 rdf:type schema:DefinedTerm
62 sg:pub.10.1007/s10549-010-0788-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027199206
63 https://doi.org/10.1007/s10549-010-0788-0
64 rdf:type schema:CreativeWork
65 https://doi.org/10.1093/annonc/mdq230 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042683953
66 rdf:type schema:CreativeWork
67 https://www.grid.ac/institutes/grid.412106.0 schema:Organization
 




Preview window. Press ESC to close (or click here)


...